Purpose: To investigate the role of intensity modulated proton therapy (IMPT) for advanced hepatocellular carcinoma in comparison with volumetric modulated arc therapy (VMAT).

Methods: An in-silico planning study was performed on 20 patients. The prescription dose was 60Gy in 6 fractions. Patients were planned with abdominal compression. IMPT plans were optimized with or without the inclusion of CT calibration (3%) and isocenter positioning (2,4,6mm) uncertainties. Plan robustness was appraised comparing rubust optimized plans vs standard plans and also in terms of the worst-case scenario. VMAT plans were optimized for 10FFF photon beams using 2 partial arcs.

Results: Target coverage was fully achieved by both VMAT and IMPT plans with a significant improvement in homogeneity (~25%) with IMPT. Integral dose was reduced of ~60% with IMPT while the conformality of the dose distributions was similar among techniques. The sparing of the organs at risk was strongly improved with IMPT although all clinical objectives were met for both techniques. The inclusion of the uncertainties in the optimization lead to some deterioration in the target dose homogeneity (from 40 to 80% worse with 4 or 6mm position uncertainty) while none of the coverage parameters or OAR objective was violated. The worst-case scenario analysis demonstrated the risk of a major target underdosage only in the case of the most extreme errors (6mm) with D98% in average ~12% lower than the threshold.

Conclusion: IMPT with the support of abdominal compression, can be considered a viable solution also for advanced hepatocellular carcinoma patients. Great care shall be put in the minimization of the residual respiration and positioning uncertainties but the dosimetric advantage for organs at risk and the relative robustness on target coverage are promising factors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089420PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0201992PLOS

Publication Analysis

Top Keywords

advanced hepatocellular
12
hepatocellular carcinoma
12
role intensity
8
intensity modulated
8
modulated proton
8
proton therapy
8
abdominal compression
8
impt plans
8
plans optimized
8
worst-case scenario
8

Similar Publications

TRIPLET combined with microwave ablation: A novel treatment for advanced hepatocellular carcinoma.

World J Gastrointest Oncol

January 2025

Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People's Liberation Army General Hospital, Beijing 100091, China.

This editorial comments on a study by Zuo . The focus is on the efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib (the TRIPLET regimen), alongside microwave ablation therapy, in treating advanced hepatocellular carcinoma (HCC). The potential application of this combination therapy for patients with advanced HCC is evaluated.

View Article and Find Full Text PDF

Advancing treatment strategies: Insights from network meta-analysis of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

World J Gastrointest Oncol

January 2025

Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404328, Taiwan.

This study examines the pivotal findings of the network meta-analysis of Zhou , which evaluated the efficacy of hepatic arterial infusion chemotherapy and combination therapies for advanced hepatocellular carcinoma (HCC). This meta-analysis suggests that therapeutic combinations have greater efficacy than do standard treatments. The article highlights the key insights that have the potential to shift current clinical practice and enhance outcomes for patients with advanced HCC.

View Article and Find Full Text PDF

Advanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way?

World J Gastrointest Oncol

January 2025

Department of General and Pediatric Surgery, Bolzano Central Hospital - SABES, Bolzano 39100, Trentino-Alto Adige, Italy.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with advanced stages posing significant treatment challenges. Although hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising modality for treating advanced HCC, particularly in Asian clinical practice, its adoption in Western medicine remains limited due to a lack of large-scale randomized controlled trials. This editorial reviews and comments on the meta-analysis conducted by Zhou , which evaluates the efficacy and safety of HAIC and its combination strategies for advanced HCC.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) is the most common form of liver cancer that has limited treatment options and a poor prognosis. Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage HCC but can induce tumour hypoxia, thereby promoting angiogenesis. Recent studies suggested that combining TACE with anti-angiogenic therapies and immunotherapy might improve efficacy.

View Article and Find Full Text PDF

Background: Sorafenib is a first-line treatment option for patients with hepatocellular carcinoma (HCC). However, the impact of sorafenib resistance type on patient survival prediction and choice of second-line treatment regimen is unknown.

Objectives: This study aims to explore the factors predicting resistance in patients with HCC receiving sorafenib, the impact of resistance on survival, and the optimal second-line treatment regimen.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!